Corcept Therapeutics Incorporated
$46.34
▲
1.21%
2026-04-21 06:10:01
www.corcept.com
NCM: CORT
Explore Corcept Therapeutics Incorporated stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.9 B
Current Price
$46.34
52W High / Low
$91 / $28.66
Stock P/E
49.18
Book Value
$6.11
Dividend Yield
—
ROCE
6.68%
ROE
15.02%
Face Value
—
EPS
$0.82
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
730
Beta
0.25
Debt / Equity
0.94
Current Ratio
2.92
Quick Ratio
2.85
Forward P/E
26.06
Price / Sales
5.86
Enterprise Value
$4.09 B
EV / EBITDA
89.06
EV / Revenue
5.37
Rating
Buy
Target Price
$67.4
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Wave Life Sciences Ltd. | $7.58 | — | $1.43 B | — | -39.63% | -54.97% | $21.73 / $5.02 | $2.76 |
| 2. | Innoviva, Inc. | $23.92 | 6.53 | $1.77 B | — | 10.33% | 29.09% | $25.14 / $16.52 | $15.71 |
| 3. | Silexion Therapeutics Corp | $1.08 | — | $3.63 M | — | -260.98% | 1718.9% | $22.36 / $0.97 | $0.83 |
| 4. | Mineralys Therapeutics, Inc. | $30.07 | — | $2.52 B | — | -26.38% | -36.91% | $47.65 / $12.59 | $7.93 |
| 5. | Gain Therapeutics, Inc. | $2.12 | — | $89.98 M | — | -96.12% | -1.56% | $4.34 / $1.41 | $0.44 |
| 6. | Rani Therapeutics Holdings, Inc. | $0.97 | — | $118.3 M | — | -83.37% | -1.82% | $3.87 / $0.39 | $0.34 |
| 7. | Alector, Inc. | $2.71 | — | $298.53 M | — | -69.73% | -1.82% | $3.4 / $0.9 | $0.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 202.12 M | 207.64 M | 194.43 M | 157.21 M | 181.89 M | — |
| Operating Profit | 4.49 M | 10.22 M | 26.68 M | 3.42 M | 25.26 M | — |
| Net Profit | 24.29 M | 19.67 M | 35.15 M | 20.55 M | 30.75 M | — |
| EPS in Rs | 0.23 | 0.18 | 0.33 | 0.19 | 0.29 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 761.41 M | 675.04 M | 482.38 M | 401.86 M |
| Operating Profit | 44.8 M | 136.95 M | 107.28 M | 112.63 M |
| Net Profit | 99.65 M | 141.21 M | 106.14 M | 101.42 M |
| EPS in Rs | 0.94 | 1.33 | 1 | 0.95 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 836.65 M | 840.55 M | 621.52 M | 583.43 M |
| Total Liabilities | 188.85 M | 160.96 M | 114.81 M | 81.59 M |
| Equity | 647.8 M | 679.59 M | 506.7 M | 501.84 M |
| Current Assets | 485.46 M | 471.6 M | 458.64 M | 499.25 M |
| Current Liabilities | 166.09 M | 140.77 M | 104.5 M | 72.49 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 142 M | 198.29 M | 126.68 M | 120.32 M |
| Investing CF | 69.76 M | -177.6 M | 90.91 M | -114.33 M |
| Financing CF | -220.37 M | -28.35 M | -148.72 M | -17.28 M |
| Free CF | 141.78 M | 196.12 M | 126.54 M | 119.91 M |
| Capex | -0.21 M | -2.17 M | -0.14 M | -0.41 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 39.94% | 20.04% | — | — |
| Earnings Growth % | 33.04% | 4.66% | — | — |
| Profit Margin % | 20.92% | 22% | 25.24% | — |
| Operating Margin % | 20.29% | 22.24% | 28.03% | — |
| Gross Margin % | 98.39% | 98.66% | 98.66% | — |
| EBITDA Margin % | 20.49% | 22.73% | 28.89% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.